Design Therapeutics, Inc. — Q3 2023 Form 10-Q
Business context and reporting period. This unaudited quarterly report covers the three and nine months ended September 30, 2023. Design Therapeutics is a pre-revenue biopharmaceutical company developing GeneTAC small-molecule candidates for inherited nucleotide repeat expansion diseases. Following withdrawal of DT-216’s IND in October 2023, all programs were in nonclinical development or discovery.
Financial results and liquidity
| Metric | Q3 2023 | Q3 2022 | Nine months 2023 | Nine months 2022 |
|---|---|---|---|---|
| Revenue | None reported | None reported | None reported | None reported |
| Research and development expense | $13.3 million | $14.3 million | $46.1 million | $34.4 million |
| General and administrative expense | $5.6 million | $4.9 million | $17.0 million | $13.8 million |
| Total operating expenses | $18.8 million | $19.2 million | $63.1 million | $48.2 million |
| Other income, net | $3.0 million | $1.5 million | $8.0 million | $2.2 million |
| Net loss | $15.8 million | $17.7 million | $55.0 million | $46.0 million |
| Net loss per share, basic and diluted | $0.28 | $0.32 | $0.98 | $0.83 |
| Net cash used in operating activities | Not separately stated | Not separately stated | $45.8 million | $36.2 million |
Balance sheet and funding. At September 30, 2023, cash and cash equivalents were $27.9 million and investment securities were $263.0 million, totaling approximately $290.9 million, versus $330.4 million combined at December 31, 2022. Accumulated deficit was $165.8 million. Total liabilities were $14.9 million; the filing reports no borrowings or other debt. Current assets were $294.5 million and current liabilities $12.4 million.
For the first nine months, cash used in operations was $45.8 million. Investing activities provided $47.0 million, primarily reflecting investment-security maturities exceeding purchases; financing activities provided $0.2 million. Management said available resources were expected to fund anticipated requirements for more than 12 months following issuance of the financial statements. The company expects continued losses and says additional financing will be needed to complete development and commercialization.
No revenue or gross margin is reported, so product margins are not applicable. No quarterly cash-flow figure is separately provided in the filing text.
Material changes versus comparable periods
- Q3 operating expenses declined $0.4 million year over year, as lower DT-216 clinical costs following trial completion more than offset higher personnel-related expense and G&A.
- For the first nine months, operating expenses rose $14.9 million year over year, driven by FA program advancement, early-stage programs, staffing and stock-based compensation. Net loss increased $9.1 million.
- Cash and investments decreased approximately $39.5 million from year-end 2022. Operating cash use increased by $9.5 million compared with the prior-year period.
Outlook, development, risks and unusual items
- DT-216 / Friedreich ataxia: The completed Phase 1 multiple-ascending-dose study found DT-216 generally well tolerated, with no treatment-related serious adverse events or treatment-related discontinuations. Five cases of injection-site thrombophlebitis were reported across dose cohorts; all adverse events were mild or moderate. At 300 mg, exploratory muscle FXN mRNA results showed a significant increase versus placebo two days after the third weekly dose (p<0.05). Muscle exposure was below animal-study projections but produced a pharmacodynamic response.
- The company stopped escalation at 300 mg because of concern about thrombophlebitis with higher, repeated dosing. In October 2023 it withdrew the IND for the current formulation, plans to submit a new IND for an improved formulation, and was conducting bridging nonclinical studies before a planned multiple-dose Phase 1 study. Timing and success are uncertain.
- In October 2023, the company initiated a strategic realignment to reduce expenses and extend its cash runway. It planned to provide an update on strategy, priorities and anticipated pipeline milestones in early 2024. The filing does not quantify the realignment’s expected savings or provide financial guidance.
- DT-168 for FECD and the DM1 program remain in nonclinical development. Management described supportive nonclinical findings but gave no clinical timelines in this filing.
- Key risks: Clinical and regulatory outcomes are uncertain; the improved DT-216 formulation may not resolve tolerability issues or enable resumed trials on the anticipated timetable. Development requires substantial future financing, which may dilute shareholders or be unavailable on acceptable terms. The company relies on third-party manufacturers and research providers, and faces competition, including an approved FA therapy.
- Commitments and related parties: Operating leases are with an entity controlled by a director; lease liabilities totaled $3.2 million. A separate consulting agreement with a company executive’s affiliated group includes a $240,000 termination fee under specified circumstances; no liability was recorded. The WARF license provides for up to $17.5 million in future regulatory and commercial milestone payments, plus potential royalties. Management reported no material contingent liabilities and no material litigation.
Most important facts for investors to verify
- Whether the improved DT-216 formulation supports a new IND, acceptable injection-site tolerability and a timely return to clinical testing.
- The results and timing of bridging nonclinical studies and the planned Phase 1 study, including how exposure and FXN response compare with the prior formulation.
- Specific expense reductions, restructuring costs and updated pipeline priorities following the October 2023 strategic realignment.
- Cash burn and runway under the revised operating plan, and whether additional capital will be required sooner than management expects.
- Potential dilution from the equity plans or future financing; the company reported no ATM sales through September 30, 2023.